Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
Emergent BioSolutions Inc. (NYSE:EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced the initiation of a Phase 1 clinical study to evaluate the safety,...
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook
GAITHERSBURG, Md., March 5, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2014. Financial highlights...
Emergent BioSolutions to Participate in March 2015 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in March...
Emergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55
Emergent BioSolutions Inc. (NYSE:EBS) today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to demonstrate that BioThrax® (Anthrax Vaccine Adsorbed)...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015
mergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, March 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of...
Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial Outlook
Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2014 financial results and provided guidance for...
Emergent BioSolutions to Participate in January 2015 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in January...
Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has acquired the EV-035 series of molecules from Evolva Holding SA (SIX:EVE). EV-035 is a series of novel small molecule broad spectrum...
Emergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure Prophylaxis
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the...
Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included. Revenue: Q3 2014 total revenue of $138.0...
Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11,...
Emergent BioSolutions to Release Third Quarter 2014 Financial Results and Conduct a Conference Call on November 6, 2014
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call at 5:00 pm (Eastern Time) on Thursday, November 6, 2014. The call will last approximately 1 hour. During the call, company...